exRNAdisease

General Information

Database ID:

exR0076656

RNA Name:

MCM7

RNA Type:

mRNA

Chromosome:

chr7

Starnd:

Coordinate:

Start Site(bp):

100092728

End Site(bp):

100101940

External Links:

Disease Information

Disease Name:	Fragile X Syndrome
Disease Category:	Congenital, Hereditary, and Neonatal Diseases and Abnormalities
MeSH ID:	D005600
Type:	Diseases Category/Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Alias:	Fragile X Syndromes//Syndrome, Fragile X//Syndromes, Fragile X//Marker X Syndrome//Marker X Syndromes//Syndrome, Marker X//Syndromes, Marker X//Mental Retardation, X-Linked, Associated With Marxq28//X-Linked Mental Retardation and Macroorchidism//X Linked Mental Retardation and Macroorchidism//Fragile X Mental Retardation Syndrome//Martin-Bell Syndrome//Martin Bell Syndrome//Syndrome, Martin-Bell//Fra(X) Syndrome//FRAXE Syndrome//FRAXE Syndromes//Syndrome, FRAXE//Syndromes, FRAXE//Mental Retardation, X-Linked, Associated With Fragile Site Fraxe//Fragile X-F Mental Retardation Syndrome//Mar (X) Syndrome//FRAXA Syndrome//FRAXA Syndromes//Syndrome, FRAXA//Syndromes, FRAXA

Expression Detail

GEO ID:	GSE83556
Description:	Global transcriptome dysregulation in second trimester fetuses with FMR1 expansions
Experimental Design:	Disease vs Control
Case Disease Type:	Fragile X Syndrome
Case Disease SubType:	NA
Case Sample:	Fragile X Syndrome
Control Sample:	Normal
Number of Case:	22
Number of Control:	18
Number of Samples:	40

Regulatory Relationship

mRNA targets:

Gene Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AAR2	chr20	36236459	36270918	+
AC010422.5	chr19	12664828	12669397	-
AC037459.1	chr8	22589274	22602084	+
AC073508.2	chr17	40627356	40665141	-
AC091551.1	chr18	50968019	51058144	+
AC131160.1	chr3	183815568	183884889	-
AC245033.1	chr15	82536788	82573194	-
ACADS	chr12	120725774	120740008	+
ACIN1	chr14	23058564	23095614	-
ACTN3	chr11	66546395	66563334	+
ACVR1B	chr12	51951699	51997078	+
ADAMTS1	chr21	26835755	26845409	-
ADD2	chr2	70607618	70768225	-
ADGRV1	chr5	90529344	91164437	+
ADPGK	chr15	72751369	72785846	-
AGO2	chr8	140520156	140635633	-
AHCY	chr20	34280268	34311802	-
AIF1L	chr9	131096476	131123152	+
AKT2	chr19	40230317	40285536	-
AL513165.2	chr9	37512547	37592469	-
ALDH18A1	chr10	95605941	95656711	-
ALDH9A1	chr1	165662216	165698863	-
ALDOA	chr16	30064164	30070457	+

miRNA targets:

miRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
hsa-miR-93-5p	chr7	100093815	100093837	-
hsa-miR-25-5p	chr7	100093610	100093630	-
hsa-miR-6790-3p	chr19	6392925	6392945	-

circRNA targets:

lncRNA targets:

lncRNA Symbol	Chromosome	Start Site(bp)	End Site(bp)	Strand
AC004687.1	chr17	58330884	58332508	-
AC016876.2	chr17	7581964	7584086	-
AC091493.1	chr3	16687986	16697479	-
AC091564.7	chr11	6610883	6616594	-
AC106864.1	chr4	112693047	112706810	-
AC132217.1	chr11	2129121	2129964	-

Display:

Experiment Detail

GEO ID:	GSE83556
Sample Source:	Amniotic Fluid
Source Fraction:	Supernatant
Platform:	GPL570
Method:	Microarray
Num of detected RNA Type:	1
Num of detected RNAs of this Type:	17063
Sample treatment protocol:	RNA was extracted from 5-15 mL amniotic fluid supernatant (centrifugation at 350g, 4C, 10, min).
RNA Extract protocol:	All samples were processed using the Qiagen Circulating Nucleic Acid kit with an on-column DNase digestion step to remove genomic DNA. The RNA was then purified and concentrated with the RNeasy MinElute Clean up kit and eluted in RNasefree water.
RNA library preparation protocol:	RNA was converted to cDNA and amplified using the Ovation Pico WTA kit V2 and then purified with the QIAquick PCR Purification kit. Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA)Samples were labeled using the Encore Biotin Module (NuGEN, San Carlos, CA).

Reference